Assistance Publique - Hôpitaux de Marseille
Marseille, 13005, France
Location status: Recruiting
NCT Number: NCT07049588
This is a 2-year follow-up study of a cohort of 35 CMT1A patients and 20 healthy volunteers. The main objective is identifying prognostic markers for CMT1A using multi-omics analysis. The study is recruiting subjects between the ages of 10 and 30.
The most common inherited neuropathy is Charcot-Marie-Tooth disease type 1A (CMT1A), caused by a duplication of the gene expressing PMP22. CMT1A patients develop symptoms in early childhood with variable progression and there is no established therapy until now. Therapy must start in childhood, before peripheral nerves degenerate. However, we lack easily obtainable biomarkers in early disease stages.
In CMT-MODs, we will identify disease and prognostic biomarkers in young CMT1A patients.
Interested in participating?
Request Info10 year–30 year
All sexes
Interventional
Not applicable
Marseille, 13005, France
Location status: Recruiting
The CMT-MODs project aims to conduct a multi-omics analysis (transcriptomics, proteomics, lipidomics) in young patients with early-stage CMT1A. This evaluation should enable the identification of prognostic and change-sensitive biomarkers for use in clinical trials.
A large cohort of CMT1A children, adolescents and young adults aged 10-30 years over 12 months applying the novel clinical outcome measures CMT Examination Score/CMT Neuropathy Score Version Version 2 Rasch versions (CMTES-R/CMTNSv2-R), the functional outcome measure CMT-FOM, pCMT-Qol, as well as a nerve conduction study (NCS) and quantitative MRI will be assessed.
Blood (and optional skin) samples will be taken and gene expression of the most promising candidates will be identified.
This assessment of CMT patients at early disease stages will allow CMT-MODs to establish biomarkers that may serve as a standard readout for disease severity and predict the disease course.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Quantification of biomarkers as fat fraction, magnetization Transfer Ratio, muscular volume, relaxation time T2
Performed on the arm or index finger, depending on patient age
ONLS, CMTES-R, CMT-Peds, CMT-FOM
10 ml sample
pCMT-QoL, EVA, WALK-12, PGI-c, SF-12
Time frame: Between inclusion (month 0) and one year later (month 12)
RNA seq on blood and skin tissues
Time frame: Between inclusion (month 0) and one year later (month 12)
Label-free quantitative approach on blood and skin tissues
Time frame: Between inclusion (month 0) and one year later (month12)
Time frame: Between inclusion (month 0) and one year later (month12)
Time frame: Between inclusion (month 0) and one year later (month12)
Time frame: Between inclusion (month 0) and one year later (month12)
Time frame: Between inclusion (month 0) and one year later (month12)
Overall Neuropathy Limitations Scale
Time frame: Between inclusion (month 0) and one year later (month12)
CMT Examination Score
Time frame: Between inclusion (month 0) and one year later (month12)
The CMT-Functional Outcome Measure
Time frame: Between inclusion (month 0) and one year later (month 12)
Charcot-Marie-Tooth Disease Pediatric Scale
Time frame: Between inclusion (month 0), month 6, and one year later (month12)
Pediatrics CMT Questionnaire of Life
Time frame: Between inclusion (month 0), month 6, and one year later (month 12)
Visual Analog Scale
Time frame: Between inclusion (month 0), month 6, and one year later (month 12)
Time frame: Between inclusion (month), month 6, and one year later (month 12)
Patient's Global Impression of change scale
Time frame: Between inclusion (month 0), month 6, and one year later (month12)
Interested in participating?
Request InfoAssistance Publique Hopitaux De Marseille
Other
A Multi-omic Approach to the Identification of Novel Biomarkers in Early Charcot-Marie-Tooth 1A Disease (CMT1A)
Acronym: CMT-MODS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07726043
Charcot-Marie-Tooth Disease, Charcot-Marie-Tooth Disease Type 1A
Marseille, France
View Trial DetailsNCT06328712
Charcot-Marie-Tooth Disease, Charcot-Marie-Tooth Disease Type 1A
Gyeongju, South Korea
View Trial DetailsNCT02596191
Charcot-Marie-Tooth Disease, Charcot-Marie-Tooth Disease Type 1A
Marseille, France
View Trial DetailsNCT02967679
Anti-MAG Neuropathy, Autoimmune Diseases
Créteil, France
View Trial Details